NCT02191176已完成1 期
A Phase I Multiple Dose Trial to Investigate Safety With Special Emphasis on ECG Effects and Tolerability After Oral Doses of 30 mg q.i.d. and 90 mg q.i.d. Dextromethorphan Hydrobromide Monohydrate (2 mg/mL Syrup) in Healthy Male and Female Subjects for 2 Days Followed by a Morning Dose (Extensive Metabolisers of CYP 2D6) and for 10 Days Followed by a Morning Dose (Poor Metabolisers of CYP 2D6) (Randomised, Double-blind, Placebo-controlled Groups)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 48
- 主要终点
- Number of patients with abnormal changes in laboratory parameters
研究概览
简要总结
The primary objective of the current study is to investigate the safety with special emphasis on ECG effects, and tolerability of dextromethorphan hydrobromide monohydrate (2mg/mL syrup) in healthy male and female subjects following oral administration of 30 mg q.i.d. and 90 mg q.i.d. for 2 days followed by a single morning dose (extensive metabolisers of CYP 2D6) and for 10 days followed by a single morning dose (poor metabolisers of CYP 2D6).
Additionally pharmacokinetic properties of dextromethorphan and its main metabolites dextrorphan, 3-hydroxymorphinan, and 3-methoxymorphinan will be investigated
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy males and females according to the following criteria: Based upon a complete medical history, including the physical examination, oral body temperature, vital signs (blood pressure, pulse rate), 12-lead Electrocardiogram (ECG), clinical laboratory tests
- •Age ≥18 and Age ≤55 years
- •BMI ≥18.5 and BMI ≤30 kg/m2 (Body Mass Index)
- •Extensive or poor metabolisers for CYP 2D6 based on the results of a genotyping test
- •Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation
排除标准
- •Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
- •Any evidence of a clinically relevant concomitant disease
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Surgery of the gastrointestinal tract (except appendectomy)
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
- •Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- •Use of drugs which might reasonably influence the results of the trial or that prolong the QT/QTc interval based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
- •Participation in another trial with an investigational drug within one month prior to first administration or during the trial
- •Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
- •Inability to refrain from smoking on trial days
- •Alcohol abuse (more than 60 g/day)
- •Drug abuse
- •Blood donation (more than 100 mL within four weeks prior to first administration or during the trial)
- •Excessive physical activities (within one week prior to first administration or during the trial)
- •Any laboratory value outside the reference range that is of clinical relevance
- •Inability to comply with dietary regimen of trial site
- •A marked baseline prolongation of QTc interval of >450 ms;
- •A history of additional risk factors for Torsades de points (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
- •Exclusion criteria specific for this study:
- •Use of drugs that inhibit or induce cytochrome P 450 enzymes, especially CYP2D6, within 30 days prior to first administration of the study medication or during the trial
- •For female subjects:
- •Pregnancy or planning to become pregnant within 2 months of study completion
- •Positive pregnancy test
- •No adequate contraception in woman of child bearing potential during the study, i.e., sterilisation, intrauterine device, injectables, oral contraceptive combined with a barrier method of contraception
- •Lactation period
研究组 & 干预措施
Dextromethorphan syrup - low dose
Experimental
干预措施: Dextromethorphan syrup - low dose (Drug)
Dextromethorphan syrup - high dose
Experimental
干预措施: Dextromethorphan syrup - high dose (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Number of patients with abnormal changes in laboratory parameters
时间窗: up to day 20
Number of patients with clinically significant changes in vital signs (blood pressure and pulse rate)
时间窗: up to day 20
Number of patients with clinically significant changes in 12-lead ECG (electrocardiogram) including QT interval and heart rate corrected QTcN, QTcF (Fridericia) and QTcB (Bazett)
时间窗: up to day 20
Number of patients with adverse events
时间窗: up to 48 days
Number of patients with abnormal findings in physical examination
时间窗: up to day 20
Assessment of tolerability by investigator on a 4-point scale
时间窗: day 20 (end of trial examination)
次要结局
- tmax (time from dosing to the maximum concentration of the analyte in plasma) after the first dose(within 5 hours after first drug administration)
- Cmax,N (maximum measured concentration of the analyte in plasma following the Nth dose) after the last dose(up to day 13)
- tmax,N (time from last dosing to the maximum concentration of the analyte in plasma following the Nth dose) after the last dose(up to day 13)
- Cmax (maximum measured concentration of the analyte in plasma) after the first dose(within 5 hours after first drug administration)
- MRTpo,N (mean residence time of the analyte in the body after oral administration of the Nth dose) after the last dose(up to day 13)
- AUCt1-t2,N (area under the concentration-time curve of the analyte in plasma from the time interval t1 to t2 following the Nth dose) after the last dose(up to day 13)
- AUCt1-t2 (area under the concentration-time curve of the analyte in plasma from the time interval t1 to t2) after the first dose(within 5 hours after first drug administration)
- AUC0-5,N (area under the concentration-time curve of the analyte in plasma over the time interval 0 to 5 hours following the Nth dose) after last dose(up to day 13)
- λz,N (terminal rate constant in plasma following the Nth dose) after the last dose(up to day 13)
- Cmax (maximum observed concentration of the analyte in plasma) after the second dose(Day 1)
- AUC0-5 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 5 hours after administration) after the first dose(within 5 hours after first drug administration)
- t1/2,N (terminal half-life of the analyte in plasma following the Nth dose) after the last dose(up to day 13)
- tmax (Time to Cmax of the analyte in plasma) after the second dose(Day 1)
研究者
相似试验
已完成
1 期
Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid TumorsAdvanced or Metastatic Solid TumorNCT03517956Bayer16
已完成
1 期
Study to Evaluate the Safety, Tolerance, Pharmacokinetics Characteristics of PA3670 Tablets in Chinese Healthy SubjectsChronic HBV InfectionNCT05851261Zhejiang Palo Alto Pharmaceuticals, Inc.60
已完成
1 期
PK, Safety & Tolerability of CyCol® Versus Sandimmune® in Healthy SubjectsHealthyNCT02130414Sigmoid Pharma48
已完成
1 期
A Study to Assess Safety and Tolerability of GS1-144 in Healthy VolunteersVasomotor SymptomsAdult Healthy VolunteersNCT06204250Changchun GeneScience Pharmaceutical Co., Ltd.86
已完成
1 期
Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)CancerNCT00112372Merck Sharp & Dohme LLC147